Cost-Effectiveness Analysis of 177 Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care Perspective

Journal of Nuclear Medicine 2026 Open access

Read full text
Authors: Kemal C. Gogebakan, Natalia Kunst, Alireza Ghodsi, Lukas Owens, Amir Iravani, Ruth Douglas Etzioni
DOI: 10.2967/jnumed.125.271825
Cited by: 5
References: 25

Abstract

Lu-PSMA-617 was not cost-effective compared with cabazitaxel in the base case analysis, it may achieve cost-effectiveness under more favorable assumptions of survival benefit or reduced cost per cycle. Probabilistic analyses further highlighted substantial uncertainty, with a low likelihood of cost-effectiveness.

Fields of Study & Subjects

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Economic and Financial Impacts of Cancer

Publication details

Journal / source
Journal of Nuclear Medicine
Publisher
Society of Nuclear Medicine
Volume
67
Issue
6
Pages
936–942
Publication date
19 March 2026
Language
EN